RT Journal Article
SR Electronic
T1 Efficacy of remdesivir in Japanese patients hospitalised with COVID-19: A large observational study using the COVID-19 Registry Japan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.09.21253183
DO 10.1101/2021.03.09.21253183
A1 Shinya Tsuzuki
A1 Kayoko Hayakawa
A1 Nobuaki Matsunaga
A1 Mari Terada
A1 Setsuko Suzuki
A1 Hiroshi Ohtsu
A1 Yusuke Asai
A1 Koji Kitajima
A1 Sho Saito
A1 Yukari Uemura
A1 Taro Shibata
A1 Masashi Kondo
A1 Kazuo Izumi
A1 Masayuki Hojo
A1 Tetsuya Mizoue
A1 Kazuhisa Yokota
A1 Fukumi Nakamura-Uchiyama
A1 Fumitake Saito
A1 Wataru Sugiura
A1 Norio Ohmagari
YR 2021
UL http://medrxiv.org/content/early/2021/03/10/2021.03.09.21253183.abstract
AB Objectives Results from several randomised controlled trials comparing the efficacy of remdesivir with placebo have been reported. Data on the efficacy of remdesivir in Asian populations are limited, and conflicting results have been reported. The aim of the present study is to examine whether remdesivir is effective for the treatment of COVID-19 or not.Methods We evaluated the efficacy of remdesivir from data acquired from the COVID-19 Registry Japan, a nationwide registry of Japanese patients hospitalised with COVID-19, using five-to-one propensity score (PS) matching. Primary outcomes were overall risk of fatality, risk of invasive mechanical ventilation or extracorporeal membrane oxygenation (IMV/ECMO) and length of stay (LoS) in healthcare facilities.Results In total, 1907 of 15,225 patients met our inclusion criteria. After PS matching, 74 patients were assigned to the remdesivir case group and 195 patients to the non-remdesivir control group. In a PS-matched cohort, fatality risk (12.2% vs 13.3%; P = 1.0); risk of IMV/ECMO (5.4% vs 4.6%; P = 0.757); length of intensive care unit stay (6 vs 6 days; P = 0.473) and length of IMV (13 vs 5 days; P = 0.509) were not different between the case and control groups. LoS in the case group was longer than in the control group (14 vs 11 days; P < 0.001).Conclusions This study suggested that remdesivir may have no positive effect on clinical outcomes and reductions in invasive/non-invasive respiratory support for patients with COVID-19 in Japan.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Health and Labour Sciences Research Grant, Research for risk assessment and implementation of crisis management functions for emerging and re-emerging infectious diseases.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the NCGM ethics review board (NCGM-G-003494-0).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this study would be available upon a reasonable request to the corresponding author.